Items Tagged with 'Pfizer Inc. (NYSE: PFE)'


PFE Complete $11.85 billion Sale

Pfizer Completes Sale of Nutrition Business to Nestlé

On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.

Read More
PFE Announces Revenues of $14.0 billion

Pfizer Reports Third-Quarter 2012 Results

On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.

Read More
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.

Read More
Pfizer Buys Vitamin C Icon

Pfizer Acquisition Announced

On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....

Read More

Pfizer Recall Announced

On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.

Read More

Pfizer FDA Approval Received

On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Read More

Pfizer Trial Results Announced

On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.

Read More

Pfizer FDA Approval Granted

On December 30, 2011, Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. 

Read More

Free Report

George Putnam has suceessfully invested in distressed companies for nearly 30 years and The Turnaround Letter's market-beating returns demonstrate the profit potential. He knows all the pitfalls, too--which he shares in this free report!

stock market advice

stock market advice

Distressed Investing Blog

Distressed Investing Blog

The China Syndrome: Stock Market Volatility & Turnaround Investing Strategy, Part II

We believe that it is very important not to let the market volatility spook you into bailing out of stocks or taking other similar drastic action. While it may be painful to ride out a sharp downturn, that is the best strategy. The market will recover from any of these downdrafts, usually quite quickly. Read More.

Your Financial Security is Serious Business...

so why should you trust The Turnaround Letter?

  • Ranked as #1 Performing Newsletter for 15-Yr. Returns: Turnaround Letter's 12.3% vs. S&P's 2.2%
  • 29+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
  • Diverse Monthly Stock Picks Personally Selected by George Putnam

2015 Stock Profit

George Putnam's Turnaround Letter has enjoyed market-beating returns for nearly 30 years now and 2015 is no different: 10 of this year's 12 sale recommendations have seen increases--with four of those 100% or higher. Despite recent stock market turbulence, 2015's closed out stock picks have realized an average gain of 69% thus far.


The chart below reflects The Turnaround Letter's past five sale recommendations.


Most Recent Value Stock Returns


Value Stock Profit